The correlation between histopatology severity score, expression of JAK1 and expression of STAT3 in psoriasis vulgaris
Abstract
Background Psoriasis vulgaris diagnosis and severity are currently considered as less objective. Histopathological scoring using Trozak's score is a quantitative assessment which is considered to represent the disease's process. Janus Kinase (JAK) 1 and Signal Transducer and Activator of Transcription (STAT) 3 examinations in psoriasis vulgaris is also currently considered to represent the diseases’ process and severity. Objective To analyze the correlation between JAK1 and STAT3 expression with the severity of psoriasis vulgaris as determined by the Trozak score on paraffin block with psoriasis vulgaris features. Methods This was retrospective cross-sectional study on 37 paraffin blocks with psoriasis vulgaris features at the Department of Dermatology and Venereology and Pathology Anatomy of RSUD Dr. Soetomo Surabaya. The results of the biopsy in the form of paraffin blocks were re-cut, stained with Hematoxylin & Eosin (HE), anti-JAK1, and anti-STAT3 antibodies. Psoriasis vulgaris severity was determined histopathologically by Trozak score. Immunohistochemical score was calculated from the total score of fluorescent cells after staining with anti-JAK1 and anti-STAT3 antibodies. Correlation analysis was performed with Spearman test, with p<0.05 considered significant. Results Thirty-seven biopsies were from 21 (56.76%) female patients and 16 (42.2%) male patients were collected, with the highest incidence found in the 45-60 years age group (43.2%). No significant correlation was found between the increase in JAK1 and STAT3 scores with an increase in Trozak scores on paraffin block with psoriasis vulgaris features. Conclusion No significant correlation between Trozak score, JAK1, and STAT3 were found on paraffin blocks with psoriasis vulgaris features.References
Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015;5(93):2–6.
Bai S, Srinivasan S. Histopathologic diagnostic parameters of psoriasis; a clinicopathological study. Int J Res Med Sci. 2016;4(6):1915–20.
Farag AGA, Samaka R, Elshafey EN, Shehata WA, El Sherbiny EG, Hammam MA. Immunohistochemical study of janus kinase 1/signal transducer and activator of transcription 3 in psoriasis vulgaris. Clin Cosmet Investig Dermatol. 2019;12:497–508.
Gudjonsson J, Elder J. Psoriasis. In: Kang S, Amagai M, Bruckner A, Enk A, Margolis D, McMichael A, et al., editors. Fitzpatrick’s Dermatology. 9th ed. New York: McGraw Hil Education; 2019. p. 457–97.
Wan MT, Pearl RL, Fuxench ZCC, Takeshita J, Gelfand JM. Anticipated and Perceived Stigma Among Patients With Psoriasis. J Psoriasis Psoriatic Arthritis. 2020;5(3):93–9.
Kaufman BP, Alexis AF. Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial/ethnic groups. Am J Clin Dermatol. 2018;19(3):405–23.
Coimbra S, Santos-Silva A. Biomarkers of psoriasis severity and therapy monitoring. World J Dermat. 2014;3(2):15–27.
Kim BY, Choi JW, Kim BR, Youn SW. Histopathological findings are associated with the clinical types of psoriasis but not with the corresponding lesional psoriasis severity index. Ann Dermatol. 2015;27(1):26–31.
Setyowatie L, Sukanto H, Murtiastutik D. C-reactive protein pada berbagai derajat keparahan psoriasis vulgaris. Berk Ilmu Kesehat Kulit dan Kelamin. 2016;28(2):1–9.
Paul C, Gourraud PA, Bronsard V, Prey S, Puzenat E, Aractingi S, et al. Evidence-based recommendations to assess psoriasis severity: Systematic literature review and expert opinion of a panel of dermatologists. J Eur Acad Dermatology Venereol. 2010;24(Suppl. 2):2–9.
Trozak DJ. Histologic grading system for psoriasis vulgaris. Int J Dermatol. 1994;33(5):380-1.
doi: 10.1111/j.1365-4362.1994.tb01073.x.
Howell MD, Kuo FI, Smith PA. Targeting the Janus Kinase Family in Autoimmune Skin Diseases. Front Immunol. 2019;10:2342.
Coimbra S, Oliveira H, Figueiredo A, Rocha-Pereira P, Santos-Silv A. Psoriasis: epidemiology, clinical and histological Features, triggering factors, assessment of severity and psychosocial aspects. Psoriasis- A Syst Dis. InTech; 2012. Available from: http://dx.doi.org/10.5772/26474
AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis – comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566–71.
Chau T, Parsi KK, Ogawa T, Kiuru M, Konia T, Li C-S, et al. Psoriasis or not? Review of 51 clinically confirmed cases reveals an expanded histopathologic spectrum of psoriasis. J Cutan Pathol. 2017;44(12):1018–26.
Eysteinsdóttir JH, Ólafsson JH, Agnarsson BA, Jónasdóttir S, Sigurgeirsson B. Trozak Histological Assessment Score of Psoriasis Vulgaris: Cor_relation with Disease Severity, Other Histological Findings and Quality of Life Assessment. Clin Exp Dermatol. 2017;2017(2):1–7.
Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341–52.
Calautti E, Avalle L, Poli V. Psoriasis: A STAT3-centric view. Int J Mol Sci. 2018;19(1):1–14.
Andrés RM, Hald A, Johansen C, Kragballe K, Iversen L. Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity. Exp Dermatol. 2013;22(5):323–8.
Fridman JS, Scherle PA, Collins R, Burn T, Neilan CL, Hertel D, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol. 2011;131(9):1838–44.
Available from: http://dx.doi.org/10.1038/jid.2011.140
Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402.
Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012(iv):561018.
